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Abstract Relapse after completing adjuvant tamoxifen
therapy is a persistent threat for women with hormone-
responsive breast cancer. Third-generation aromatase
inhibitors, such as letrozole, provide a new option for
extended adjuvant hormonal therapy after 5 years of
tamoxifen. MA.17 was conducted to determine whether
letrozole improves outcome after discontinuation of
tamoxifen. Postmenopausal women with hormone recep-
tor-positive breast cancer (N = 5,187) were randomized to
letrozole 2.5 mg or placebo once daily for 5 years. At a
median follow-up of 30 months, letrozole signiﬁcantly
improved disease-free survival (DFS; P\0.001), the pri-
mary end point, compared with placebo (hazard ratio [HR]
for recurrence or contralateral breast cancer 0.58; 95%
conﬁdence interval [CI] 0.45, 0.76] P\0.001). Further-
more, letrozole signiﬁcantly improved distant DFS
(HR = 0.60; 95% CI 0.43, 0.84; P = 0.002) and, in women
with node-positive tumors, overall survival (HR = 0.61;
95% CI 0.38, 0.98; P = 0.04). Clinical beneﬁts, including
an overall survival advantage, were also seen in women
who crossed over from placebo to letrozole after unblin-
ding, indicating that tumors remain sensitive to hormone
therapy despite a prolonged period since discontinuation of
tamoxifen. The efﬁcacy and safety of letrozole therapy
beyond 5 years is being assessed in a re-randomization
study, following the emergence of new data suggesting that
clinical beneﬁt correlates with the duration of letrozole.
MA.17 showed that letrozole is extremely well-tolerated
relative to placebo. Letrozole should be considered for all
women completing tamoxifen; new results from the post-
unblinding analysis suggest that letrozole treatment should
also be considered for all disease-free women for periods
up to 5 years following completion of adjuvant tamoxifen.
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Introduction and rationale
There is a persistent risk of breast cancer recurrence fol-
lowing primary treatment [1–3]. Initially, patients with
hormone receptor-positive (HR+) breast tumors have a
lower risk of recurrence than those with HR– tumors, but
with longer follow-up, the opposite may be the case [3, 4].
For example, Saphner showed that the signiﬁcantly higher
hazard of recurrence in HR– versus HR+ patients in the
time period 0–12 years (P\0.00001) could be explained
by the higher risk of recurrence in years 0–5 for HR–
patients (P\0.0001). However, between years 3 and 4,
the hazard of recurrence for HR– and HR+ patients
crossed, and beyond 5 years was actually higher for HR+
patients (P = 0.00002) [4]. These data clearly indicate the
need for continuous hormonal treatment for women with
HR+ tumors.
The beneﬁts of adjuvant hormonal treatment with tamox-
ifenwereﬁrstdemonstratedintheNationalSurgicalAdjuvant
Breast and Bowel Project (NSABP) B-14 trial [5]. This large
randomized, double-blind, placebo-controlled trial involving
patientswithnode-negative,HR+breastcancerdemonstrated
a signiﬁcant prolongation of disease-free survival (DFS)
among women treated with tamoxifen for 5 years, as com-
pared with those receiving placebo. Updated results with
longer follow-up demonstrated that the 5-year beneﬁt in DFS
with tamoxifen persisted through at least 10 years of follow-
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DOI 10.1007/s10549-007-9698-1up, and a statistically signiﬁcant survival beneﬁt was also
observed [6]. However, since the optimal duration of tamox-
ifen therapy was not known, patients who had completed
5 years of tamoxifen therapy and were disease-free were
re-randomized to receive placebo or tamoxifen. Results pub-
lished with a follow-up of 7 years after reassignment
demonstrated a disadvantage in patients who continued
tamoxifen compared with those who discontinued: DFS was
78vs.82%,respectively(P = 0.03),andoverallsurvival(OS)
was 91 vs. 94% (P = 0.07). Thus, extending tamoxifen
treatment beyond 5 years was not deemed beneﬁcial [7]n o r
recommended [8] when the MA.17 trial was initiated.
While clearly in the best interest of patients, discontin-
uation of tamoxifen after 5 years creates a therapeutic
dilemma because of the persistent risk of breast cancer
recurrence. Relapse or appearance of new tumors after
completion of tamoxifen therapy is relatively common in
patients with HR+ tumors [1, 2, 4, 7]. The Oxford meta-
analysis found that more than half of breast cancer recur-
rences and two thirds of breast cancer deaths occur after
5 years of adjuvant tamoxifen [3]. In the NSABP B-14
trial, the average annual rate of breast cancer recurrences
was 8.9 per 1,000 patients who discontinued tamoxifen at
5 years [7]. Patients in whom tamoxifen is discontinued
therefore require an alternative treatment option to provide
continuing protection from recurrence.
The loss of efﬁcacy seen with long-term tamoxifen
therapy may result from the emergence of a hormone-
independent tumor phenotype [9, 10] or the induction of
hypersensitivity to estradiol [11, 12]. Tamoxifen is thought
to be more susceptible than aromatase inhibitors (AIs) to
this adaptive change because of its intrinsic agonist prop-
erties [12]. Furthermore, data from the NSABP B-14 trial
suggest that residual tumor cells may become tamoxifen-
resistant, and that continued use of tamoxifen might in fact
stimulate their proliferation [6, 13].
The development of highly potent and selective third-
generation AIs provided a new hormone therapy option for
patients with HR+ breast cancer [14–16]. It is suggested in
independent studies that Letrozole (Femara
1) is the most
potent of the AIs as determined by in vitro assays [17] and
clinical studies of total body aromatization [18]. A recent
study has demonstrated that the more complete inhibition
of aromatase achieved by 2.5 mg of letrozole than by 1 mg
of anastrozole results in a greater degree of suppression of
estradiol [19]. The clinical efﬁcacy of letrozole was ini-
tially demonstrated in patients with HR+ metastatic breast
cancer. In this setting, ﬁrst-line therapy with letrozole was
shown to signiﬁcantly improve outcome compared with
tamoxifen therapy [20, 21]. While OS was not signiﬁcantly
improved (34 vs. 30 months, respectively), an exploratory
analysis of the patients that did not cross over showed
a longer survival beneﬁt for letrozole-treated patients
(35 vs. 20 months) [22]. Second-line therapy with letrozole
has also demonstrated signiﬁcant clinical beneﬁts in
patients with HR+ metastatic breast cancer in whom
tamoxifen has failed [23], and in one randomized trial
demonstrated a signiﬁcantly higher response rate than an-
astrozole in this population [24].
Data from in vivo models using MCF-7 cells transfected
with the aromatase gene have shown that letrozole is more
effective than tamoxifen and devoid of the agonist action
observed with the selective estrogen receptor modulator
[25, 26]. Although the mechanisms of estrogen blockade
are different for letrozole and tamoxifen, combining the
two agents did not increase antitumor activity in the MCF-
7 xenograft model [25]. The authors proposed that
sequential administration of tamoxifen and letrozole would
be a more effective strategy [25]. This hypothesis was
recently conﬁrmed in vivo [27]. Using the MCF-7 model, it
was demonstrated that tumors progressing on tamoxifen
responded to second-line letrozole therapy, but tumors that
progressed on letrozole did not respond to second-line
treatment with tamoxifen or fulvestrant [27].
Theevidentneedtocontinuehormonetherapyafterdiscon-
tinuation of tamoxifen in patients with HR+ primary breast
cancer andthepotentialefﬁcacy ofAIsintumorsresistantto
tamoxifenprovidedtherationalefortestingadjuvantletrozole
after5 yearsoftamoxifen.Thispaperreviewsthekeyresults
from the landmark MA.17 trial [28, 29] and discusses the
advantages of letrozole treatment after the recommended
5 years of tamoxifen therapy have been completed. To date,
letrozoleistheonlyAIapprovedintheUnitedStatesandEurope
forextendedadjuvanttherapy.
Trial design and patients
MA.17 was a phase III, randomized, double-blind, placebo-
controlled trial of letrozole as extended adjuvant therapy in
postmenopausal women with primary breast cancer who
had completed approximately 5 years of adjuvant tamoxi-
fen therapy [28, 29]. The aim of the trial was to determine
whether letrozole improves outcome after the discontinua-
tion of adjuvant tamoxifen therapy. The MA.17 trial was led
by the National Cancer Institute of Canada Clinical Trials
Group and included the North American Breast Intergroup
and the Breast International Group. Institutional review
boards of participating institutions approved the study
protocol, and all patients gave written informed consent.
Patient population
The trial enrolled 5,187 postmenopausal women with early-
stage breast cancer in whom 5 years of tamoxifen (range 4.5–
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1236 years) therapy had been completed less than 3 months
before enrollment. Eligible women had to have histologically
conﬁrmed, HR+ primary breast cancer. HR+ tumors were
deﬁned as estrogen receptor-positive (ER+) or progesterone
receptor-positive(PgR+)as determined bya level of 10 fmol/
mg of protein or a positive immunohistochemical analysis.
Women were deﬁned as being postmenopausal if they were
aged at least 50 years at the start of adjuvant tamoxifen
therapy, were \50 years of age at the start of tamoxifen
therapy but postmenopausal at the initiation of tamoxifen
therapy, were\50 years at the start of tamoxifen therapy but
had undergone bilateral oophorectomy, were premenopausal
and\50 years at the start of tamoxifen therapy but became
amenorrheic during chemotherapy or treatment with tamox-
ifen, or were any age but had postmenopausal levels of
luteinising hormone or follicle-stimulating hormone prior to
the study. All women had a good performance status and life
expectancy of at least 5 years.
Randomized trial design
Eligible women were randomly assigned to receive treat-
ment with letrozole (2.5 mg) or placebo orally daily for
5 years (see Fig. 1). Women were stratiﬁed according to
the tumor HR status (positive or unknown), lymph-node
status (negative, positive, or unknown), and receipt or
nonreceipt of previous adjuvant chemotherapy. Explor-
atory sub-analyses were based on these stratiﬁcation factors
and two additional covariates (criteria for the deﬁnition of
postmenopausal status at the start of tamoxifen treatment
and duration of tamoxifen treatment).
End points and rules for interim analyses
The primary end point of the trial was DFS, deﬁned as the
time from randomization to the earliest recurrence of the
primary disease (in the breast, chest wall, or nodal or dis-
tant metastatic sites) or the development of a new primary
breast cancer in the contralateral breast. Secondary cancer
and death without a recurrence or a diagnosis of contra-
lateral breast cancer were not included as events. The trial
was powered to detect a 2.5% improvement in 4-year DFS
with letrozole (from 88 to 90.5%). Two interim analyses
were scheduled, and stopping rules were speciﬁed a priori
for interim monitoring [30].
The secondary efﬁcacy end points of the trial were OS
(deﬁned as the time from randomization to death from any
cause), annual incidence rate of contralateral breast cancer,
long-term safety and tolerability, and overall and meno-
pause-speciﬁc quality of life (QOL). In addition, distant
DFS (DDFS), deﬁned as the time from random assignment
until the ﬁrst observation of distant metastasis, was included
as a secondary efﬁcacy end point in the ﬁnal analysis [29].
QOL and long-term safety were assessed as secondary
end points [31]. Adverse events were graded according to
the Common Toxicity Criteria of the National Cancer
Institute (version 2.0). QOL was assessed with the Medical
Outcomes Study 36-Item Short Form General Health Sur-
vey (SF-36) and the Menopause-Speciﬁc Quality of Life
questionnaire [32, 33]. The effects of letrozole on lipid
proﬁle and bone mineral density (BMD) were assessed
annually in companion studies to MA.17 [34, 35].
Efﬁcacy of letrozole as extended adjuvant therapy
A total of 5,187 patients were randomized to either
letrozole (n = 2,593) or placebo (n = 2,594). Because of
noncompliance, 10 patients in the letrozole and seven in
the placebo arm were excluded from all analyses, leaving
5,170 patients (2,583 on letrozole and 2,587 on placebo) in
the time to event analysis (50 patients deemed ineligible
for several reasons and 33 with major protocol violations
were included in the analysis). The ﬁnal safety analysis
excluded 21 patients who never received study medication,
yielding a ﬁnal safety population of 5,149 patients, 2,572
receiving letrozole and 2,577 receiving placebo [29]. Based
on the 43% reduction in recurrence risk (P = 0.00008) with
letrozole seen in the ﬁrst interim analysis at 2.4 years’
median follow-up [28], the data and safety monitoring
committee recommended that the MA.17 trial be discon-
tinued early, and the participants were informed of the
results. The trial was unblinded in October 2003, and
patients on placebo were given the opportunity to switch to
letrozole. Updated efﬁcacy results after a median follow-up
of 30 months conﬁrmed the signiﬁcant clinical beneﬁts of
letrozole as extended adjuvant therapy [29]. The updated
trial results and recent additional efﬁcacy analyses of
MA.17 are summarized below. Fig. 1 MA.17 randomized trial design
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At 30 months’ follow-up, letrozole signiﬁcantly improved
DFS, the primary end point, compared with placebo (see
Fig. 2)[ 29]. The 4-DFS for patients receiving letrozole was
94.4%, compared with 89.8% for patients receiving pla-
cebo. The hazard ratio for recurrence or contralateral breast
cancer was 0.58 (95% conﬁdence interval [CI] 0.45, 0.76;
P £ 0.76), representing a 42% reduction in risk for
letrozole relative to placebo. The updated analysis also
showed that letrozole produced a statistically signiﬁcant
improvement in DDFS (hazard ratio = 0.60; 95% CI 0.43,
0.84; P = 0.002), which may be regarded as a more
meaningful end point than overall DFS; women with dis-
tant metastases inevitably die of breast cancer, and an
improvement in DDFS may therefore translate into longer
overall survival [36, 37]. Letrozole treatment non-signiﬁ-
cantly prolonged time to contralateral breast cancer
incidence, resulting in a 37.5% relative risk reduction
compared with placebo [29].
The prospectively planned subgroup analysis showed
that letrozole signiﬁcantly improved DFS in all
patients, irrespective of nodal status. The reduction in
risk of recurrence in node-positive tumors was 39%
(hazard ratio = 0.61; 95% CI 0.45, 0.84), and 55% in
those with node-negative tumors (hazard ratio = 0.45;
95% CI 0.27, 0.73). While OS was not signiﬁcantly
improved (hazard ratio = 0.82; 95% CI 0.57, 1.19;
P = 0.3), letrozole signiﬁcantly improved OS in
patients with node-positive tumors (hazard ratio = 0.61;
95% CI 0.38, 0.98; P = 0.04) (see Fig. 3), and this was
the ﬁrst survival advantage demonstrated by an AI in
early breast cancer.
Additional MA.17 analyses
Optimal duration of extended adjuvant letrozole
The ﬁnal MA.17 database, including all events up to the
date of unblinding, was analyzed to examine the relation-
ship between duration of treatment and outcomes [38, 39].
Data from this analysis have provided further evidence to
support an extended duration of letrozole, as this cohort
analysis found that the longer patients are exposed to
extended adjuvant letrozole (at least out to 48 months), the
greater the beneﬁt [39].
The risk of disease recurrence increased over time in the
placebo group, whereas in patients receiving letrozole, risk
appeared to peak at around 2 years of treatment and
decrease thereafter. In the overall patient population, hazard
ratios for events in DFS and DDFS progressively decreased
over time, favoring letrozole, with the trend being signiﬁ-
cant (P\0.0001 and P = 0.0013, respectively). The trend
for OS was not signiﬁcant but was always\1. In the 2,360
patients with node-positive status, hazard ratios for DFS,
DDFS, and OS all decreased over time, with tests for trend
all showing signiﬁcance (P = 0.0004, 0.0005, and 0.038,
respectively). Considering the 2,568 patients with node-
negative status, the hazard ratios for DFS decreased over
time, with the test for trend being signiﬁcant (P = 0.027),
whereas the hazard ratios for DDFS and OS showed no
signiﬁcant change over time (see Table 1).
Fig. 2 Kaplan–Meier curves for disease-free survival in the updated
analysis of MA.17. N, number at risk; S, survival percent, with 95%
conﬁdence intervals (CIs) in parentheses. Reprinted from ref. [29]
with permission
Fig. 3 Forest plots of the treatment effect (letrozole vs. placebo), in
terms of overall survival, in subgroups deﬁned by hormone receptor
status, lymph node status, previous chemotherapy, menopausal
criteria, and duration of tamoxifen treatment. For each subgroup,
the hazard ratio for death from any cause is plotted as a solid square,
and the area of the square is proportional to the variance of the
estimated effect. The length of the horizontal line through the square
indicates the 95% conﬁdence interval (CI). The arrow at the end of
the horizontal line indicates that the conﬁdence interval is larger than
the scale of the ﬁgure. Reprinted from ref. [29] with permission
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The intent-to-treat (ITT) analysis at 54 months’ follow-up
looked at all outcomes, including all events before and
after the unblinding, based on the original randomization of
letrozole versus placebo; it did not take into account
whether or not patients in the placebo group switched to
letrozole at the unblinding of the data. The results further
showed that patients randomized initially to letrozole had
fewer DFS events than those initially randomized to pla-
cebo [40]. Publication of the ﬁnal analysis of this data are
awaited, but these provisional results highlight the strong
beneﬁcial effect of extended adjuvant therapy with
letrozole when started immediately after tamoxifen.
Impact of HR status on clinical beneﬁt
A retrospective analysis was conducted to determine
whether HR status had an effect on the outcome of
letrozole in the extended adjuvant setting [41]. ER and PgR
positivity were deﬁned as ‡10 fmol/mg protein or positive
by immunocytochemical analysis. Preliminary results from
4,635 patients, based on local testing of HR status, showed
that the reduction in risk of recurrence with letrozole
compared with placebo was greatest in women with the
most hormone-dependent tumors. The ﬁnal results of this
analysis await publication. These results should be inter-
preted cautiously, as this was an unplanned, retrospective
analysis, and receptor levels were measured locally. Fur-
thermore, from the outset, the analysis of outcomes in
all other subgroups besides the ER+/PgR+ (n = 3,809)
patients was weakened by the low numbers of patients in
these groups (e.g., ER+/PgR–, n = 636) [42].
MA.17 post-unblinding analysis
The trial was unblinded in 2003 because DFS values were
met (stopping boundary nominal signiﬁcance, P = 0.0008)
and patients were given the opportunity to cross over. Post-
unblinding analysis of MA.17 has provided additional
efﬁcacy data on patients who had crossed over from pla-
cebo to letrozole (n = 1,655), comparing them with
patients who elected no treatment at the time of the un-
blinding (n = 613) [43]. These patients had not received
any hormonal therapy after discontinuing tamoxifen. Data
were adjusted for baseline patient and disease variables
including tumor size, nodal status, and prior adjuvant
chemotherapy. A preliminary analysis suggests that
letrozole has signiﬁcant clinical beneﬁts in patients in
whom treatment with the AI is started after a prolonged
period since the discontinuation of tamoxifen. The publi-
cation of these results is eagerly awaited as they may effect
patient care worldwide.
MA.17 re-randomization
A re-randomization of all patients completing letrozole to
receive a further 5 years of letrozole or placebo is under
way to conﬁrm this ﬁnding [40, 44]. An amendment to this
protocol allows women completing 5 years of any AI to be
re-randomized to a further 5 years of letrozole or not
regardless of prior tamoxifen or its duration. The MA.17
re-randomization study should provide additional insights
into the efﬁcacy and safety of extending letrozole therapy
beyond 5 years [45].
Safety of letrozole in the extended adjuvant setting
The women included in this trial had been disease-free for
approximately 5 years during treatment with tamoxifen
and, therefore, the safety and tolerability of continued
hormone treatment with letrozole was an important con-
sideration when the MA.17 trial was designed.
Furthermore, early unblinding of the trial has not prevented
the collection of long-term safety data, and additional sub-
studies are providing useful information on the safety
proﬁle of letrozole in the extended adjuvant setting. The
safety of AIs is discussed in detail in the paper by Dr. Perez
in this supplement.
The MA.17 trial showed that letrozole is extremely well
tolerated relative to placebo. The most common adverse
events reported were secondary to estrogen suppression
and included hot ﬂashes, myalgia, arthralgia, alopecia, and
newly diagnosed osteoporosis. The increase in newly
Table 1 Analysis of the hazard
ratios for disease recurrence
over time between the letrozole
and placebo arms of MA.17
Reprinted from ref. [38] with
permission from Elsevier
a Hazard ratios\1 indicate
values in favor of letrozole
Month after
randomization
No. at risk (letrozole/
placebo)
Hazard rate
(letrozole)
Hazard rate
(placebo)
Hazard ratio (letrozole vs.
placebo)
a
12 2,425/2,409 0.00093 0.00180 0.52 (0.40–0.64)
24 1,555/1,530 0.00105 0.00236 0.45 (0.33–0.56)
36 768/723 0.00090 0.00261 0.35 (0.21–0.48)
48 244/231 0.00059 0.00306 0.19 (0.04, 0.34)
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123diagnosed osteoporosis (8.1% for letrozole vs. 6% for
placebo; P = 0.003) [29] was predictable from the potent
suppression of estrogens by third-generation AIs [17] and
the association between estrogen levels and bone turnover
[46–48]. Of note, no signiﬁcant difference in clinical
fracture rate was seen between letrozole and placebo
groups (5.3 vs. 4.6%; P = 0.25) [29].
MA.17B is a companion study designed to compare the
effects of letrozole (n = 122) and placebo (n = 104) on
BMD in the L2–L4 (posteroanterior) region of the spine
and hip [35]. At 24 months, patients receiving letrozole
had a signiﬁcant decrease in total hip BMD (–3.6 vs
–0.71%; P = 0.044) and lumbar spine BMD (–5.35 vs.
–0.70%; P = 0.008). Further follow-up is necessary to
evaluate the long-term clinical implications of this modest
increase in bone resorption and reduction in BMD in the
spine and hip with letrozole compared with placebo. Pro-
phylactic use of the bisphosphonate zoledronic acid is
being studied as a means to prevent BMD loss [49, 50].
Results from two clinical trials have indicated that early
use of zoledronic acid effectively prevents BMD loss in
women receiving adjuvant letrozole [49, 51].
Estrogen has a beneﬁcial effect on lipid proﬁles, and it
has been suggested that AIs may have a relatively unfa-
vorable effect. However, MA.17L, a substudy of MA.17
(n = 347), demonstrated that letrozole does not signiﬁ-
cantly alter serum cholesterol, high-density lipoprotein
cholesterol, low-density lipoprotein cholesterol, triglyce-
rides, or lipoprotein (a) compared with placebo [34]. This
is in agreement with the results of the main MA.17 trial,
which showed no difference in hypercholesterolemia rates
between placebo and letrozole [28]. Importantly, in the
updated analysis of the MA.17 dataset, there were no
signiﬁcant differences between the letrozole and placebo
arms in the incidence of hypercholesterolemia (16% in
each arm; P = 0.79) or cardiovascular events (5.8 vs. 5.6%;
P = 0.76) [29].
The QOL substudy was conducted in 3,612 patients
treated in MA.17 (1,813 letrozole and 1,799 placebo) [31].
The analysis demonstrated that letrozole did not have an
adverse impact on overall QOL, as determined by SF-36,
which is an important and reassuring ﬁnding, as the
extension of letrozole treatment for up to 10 years in this
setting is now being tested [44].
Conclusions
In recent years, considerable progress has been made in
developing more effective hormonal treatments for women
with breast cancer and improving the efﬁcacy demon-
strated with tamoxifen [3]. The pioneering MA.17 trial has
demonstrated the need for extended adjuvant therapy after
5 years of tamoxifen to reduce the risk of recurrence in
postmenopausal women with HR+ breast cancer. On the
basis of this trial, letrozole was approved as extended
adjuvant therapy, and it is currently the only AI approved
for this indication [22, 52].
MA.17 demonstrated that extended adjuvant therapy
with letrozole provides women further protection against
relapse after the completion of tamoxifen. These ﬁndings
support the concept that distant micrometastases that have
survived 5 years of tamoxifen therapy remain highly
estrogen-sensitive and responsive to extended adjuvant
letrozole treatment. This is an important clinical beneﬁt in
view of the persistent risk of relapse beyond 10 years in
patients with HR+ tumors [4]. In fact, the cohort analysis
showed that in the placebo group, there was actually an
increasing risk of disease recurrence over time after dis-
continuing prior tamoxifen [40]. The preliminary MA.17
ITT data suggest that the strongest beneﬁcial effect is still
obtained when starting letrozole within 3 months of com-
pleting tamoxifen [38], while the post-unblinding results
suggest that women with hormone-dependent breast cancer
who are prescribed letrozole following a prolonged delay
after completing tamoxifen may experience a signiﬁcant
improvement in outcome [43]. Therefore, if a patient misses
the chance to start letrozole within 3 months post tamoxi-
fen, these results suggest that there is still a beneﬁt to
initiating letrozole therapy for up to 5 years following the
discontinuation of tamoxifen. Importantly, women in all
risk categories beneﬁted in terms of reduced risk for
recurrence of their cancer. Thus, in both node-positive as
well as node-negative women, there was a strong
improvement in DFS, and ‘‘low risk’’ status of the primary
tumor should not preclude consideration of extended adju-
vant therapy with letrozole. Extended therapy with adjuvant
letrozole should therefore be considered for all women
currently completing tamoxifen. In addition, in women who
have completed tamoxifen within the last 5 years, intro-
duction of letrozole for 5 years can be discussed because
although we do not have level 1 evidence for beneﬁt in this
setting as yet, our post-unblinding analysis of MA17
strongly supports the potential for beneﬁt in these women.
Among the clinical questions left unanswered are the
optimal duration of letrozole and the long-term safety of
extended adjuvant therapy in women leading a normal
healthy lifestyle. Preliminary results of a cohort study
analysis of MA.17 provide support for the use of extended
adjuvant letrozole for at least up to 4 years [40, 53]. The
MA-17 re-randomization study will assign patients com-
pleting 5 years of letrozole to a further 5 years of letrozole
or placebo and should provide data on the efﬁcacy and
safety of extending letrozole therapy beyond 5 years [45].
In conclusion, HR+ breast cancer presents an unremit-
ting threat that may require life-long hormone therapy. The
50 Breast Cancer Res Treat (2007) 105:45–53
123optimal hormone treatment strategy is evolving based on
the results of landmark clinical trials in the initial adjuvant
[54, 55], sequential adjuvant [56], and extended adjuvant
settings [28, 29]. The optimal agent, sequence of treat-
ments, or combination of treatments will be able to provide
the greatest improvement in OS with minimal acute and
long-term toxicity. MA.17 has demonstrated that letrozole
is highly effective and extremely well tolerated when given
in the extended adjuvant setting. The results of the pivotal
MA.17 trial have changed current clinical practice to
extend letrozole protective therapy in thousands of breast
cancer patients currently receiving 5 years of adjuvant
tamoxifen. The beneﬁts of long-term adjuvant letrozole
treatment clearly outweigh any adverse events in post-
menopausal women who have survived breast cancer after
initial adjuvant therapy with tamoxifen. Long-term side
effects and risks continue to be monitored and taken into
account when any individual patient is being considered for
extended adjuvant therapy.
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